Ibandronate in the treatment of prostate cancer associated painful osseous metastases

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 3, 2002, Pages 231-235

  Heidenreich, A ^a   Elert, A ^a   Hofmann, R ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bisphosphonate; Bone metastases; Cancer; Hormone refractory prostate cancer; Pain therapy

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; BICLUTAMID; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; DOXORUBICIN; ESTRAMUSTINE; ESTROGEN DERIVATIVE; FENTANYL; FLUTAMIDE; GONADORELIN DERIVATIVE; IBANDRONIC ACID; MITOXANTRONE; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INJECTION SITE; MALE; ORCHIECTOMY; PAIN ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; SIDE EFFECT; VISUAL ANALOG SCALE;

AGED; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; MALE; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 0036393344     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500574     Document Type: Article

References (30)

1. Parker SL et al. Cancer statistics 1997. CA Cancer J Clin 1997; 47: 5.
2. Issacs JT. The biology of hormone refractory prostate cancer. Urol Clin North Am 1999; 26: 263-273.
3. Smith JA, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999; 54: 8-14.
4. Clarke NW, McClure J, George NJR. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68: 74-80.
5. Body JJ et al. Current use of bisphosphonates in oncology. J Clin Oncol 1998; 16: 3890-3899.
6. Heidenreich A et al. The use of bisphosphonates for the palliative treatment of painful bone metastases due to hormone refractory prostate cancer. J Urol 2001; 165: 136-140.
7. Mühlbauer RC et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Mineral Res 1991; 6: 1003-1011.
8. Fleisch H. Bisphosphonates in Bone Disease. Stampfli, Berne, 1993.
9. Lang SH et al. Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stroma in vitro. Clin Exp Metas 1999; 17: 333-340.
10. Lang SH et al. The interaction of prostatic epithelia with human bone marrow stroma. Prostate 1998; 34: 203-213.
11. Purohit P et al. High dose intravenous pamidronate for metastastic bone pain. Br J Cancer 1994; 70: 554-558.
12. Ernst DS et al. A randomized controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997; 13: 319-326.
13. Adami S et al. Dichloromethylene diphosphonate in patients with carcinoma of the prostate metastatic to the skeleton. J Urol 1985; 134: 1152-1154.
14. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidornate: results of randomised, prospective placebo controlled study. J Urol 1989; 141: 85-87.
15. Clarke NW, McClure J, George NJR. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol 1992; 69: 64-68.
16. Cresswell S et al. Pain relief and quality of life assessment following intravenous and oral clodronate in hormone escaped prostate cancer. Br J Urol 1995; 76: 360-365.
17. Harvey A et al. The role of bisphosphonates in the treatment of bone metastases-the US experience. Support Care Cancer 1996; 4: 213-217.
18. Kylmala T et al. The effect of combined and oral clodronate on bone pain in patients with metastastatic prostate cancer. Ann Chir Gynaecol 1994; 83: 316-319.
19. Vorreuther R. Bisphosphonates as an adjunct to palliative therapy in patients with metastases from prostate carcinoma. A pilot study on clodronate. Br J Urol 1993; 72: 792-795.
20. Ralston SH. Pathogenesis and management of hypercalcaemia. In: Rubens RD, Fogelman I (eds). Bone Metastases: Diagnosis and Treatment. Springer Verlag, London, 1991, pp 99-117.
21. Ralston SH et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997; 75: 295-300.
22. Gallacher SJ et al. Breast cancer associated hypercalcaemia: a reassessment of renal calcium and phosphate handling. Ann Clin Biochem 1990; 27: 551-556.
23. Grill V et al. Parathyroid hormone related protein: elevated levels in both humoral hypercalcaemia of malignancy and hypercalcaemia complicating breast cancer. J Clin Endocrinol Metab 1991; 73: 1309-1315.
24. Urwin GH et al. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 721.
25. Clarke NW, McClure J, George NJR. Osteoblastic function and osteomalacia in metastatic prostate cancer. Eur Urol 1993; 24: 286.
26. Taube T et al. Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastasised to bone. Br J Urol 1993; 72: 98.
27. K-H Bichler et al. Investigations on bone metabolism of urological tumors forming metastases. Urol Int 1996; 56: 61-68.
28. Tannock IF et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996; 14: 1756.
29. Kanthoff PW et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506.
30. Biossier S et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949-2954.